{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:48:18Z","timestamp":1791686898646,"version":"4.3.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,11,26]],"date-time":"2010-11-26T00:00:00Z","timestamp":1290729600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Primary treatment of carcinoma of the oro-\/hypopharynx or larynx may consist of combined platinum-containing chemoradiotherapy. In order to improve clinical outcome (i.e. local control\/overall survival), combined therapy is intensified by the addition of the EGFR inhibitor cetuximab (Erbitux<jats:sup>\u00ae<\/jats:sup>). Radiation therapy (RT) is carried out as intensity-modulated RT (IMRT) to avoid higher grade acute and late toxicity by sparing of surrounding normal tissues.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods\/Design<\/jats:title>\n            <jats:p>The REACH study is a prospective phase II study combining chemoradiotherapy with carboplatin\/5-Fluorouracil (5-FU) and the monoclonal epidermal growth factor-receptor (EGFR) antibody cetuximab (Erbitux<jats:sup>\u00ae<\/jats:sup>) as intensity-modulated radiation therapy in patients with locally advanced squamous-cell carcinomas of oropharynx, hypopharynx or larynx.<\/jats:p>\n            <jats:p>Patients receive weekly chemotherapy infusions in the 1<jats:sup>st<\/jats:sup> and 5<jats:sup>th<\/jats:sup> week of RT. Additionally, cetuximab is administered weekly throughout the treatment course. IMRT is delivered as in a classical concomitant boost concept (bid from fraction 16) to a total dose of 69,9 Gy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion<\/jats:title>\n            <jats:p>Primary endpoint of the trial is local-regional control (LRC). Disease-free survival, progression-free survival, overall survival, toxicity, proteomic and genomic analyses are secondary endpoints. The aim is to explore the efficacy as well as the safety and feasibility of this combined radioimmunchemotherapy in order to improve the outcome of patients with advanced head and neck cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>ISRCTN87356938<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-10-651","type":"journal-article","created":{"date-parts":[[2010,11,26]],"date-time":"2010-11-26T07:14:12Z","timestamp":1290755652000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Treatment of locally advanced carcinomas of head and neck with intensity-modulated radiation therapy (IMRT) in combination with cetuximab and chemotherapy: the REACH protocol"],"prefix":"10.1186","volume":"10","author":[{"given":"Gregor","family":"Habl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra D","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Potthoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Uhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Hof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Hajda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Debus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Krempien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc W","family":"M\u00fcnter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,11,26]]},"reference":[{"key":"2450_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","volume":"92","author":"JP Pignon","year":"2009","unstructured":"Pignon JP, le Maitre A, Maillard E, Bourhis J, MACH-NC Collaborative Group: Meta-Analysis of Chemotherapy in Head and Neck Cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiotherapy and Oncology. 2009, 92: 4-14. 10.1016\/j.radonc.2009.04.014.","journal-title":"Radiotherapy and Oncology"},{"key":"2450_CR2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1471-2407-6-28","volume":"6","author":"W Budach","year":"2006","unstructured":"Budach W, Hehr T, Budach V, Belka C, Dietz K: A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer. 2006, 6: 28-10.1186\/1471-2407-6-28.","journal-title":"BMC Cancer"},{"issue":"9538","key":"2450_CR3","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S0140-6736(06)69121-6","volume":"368","author":"J Bourhis","year":"2006","unstructured":"Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J: Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. 2006, 368 (9538): 843-854. 10.1016\/S0140-6736(06)69121-6.","journal-title":"Lancet"},{"issue":"5","key":"2450_CR4","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/S0360-3016(01)01544-9","volume":"50","author":"S Staar","year":"2001","unstructured":"Staar S, Rudat V, Stuetzer H, Dietz A, Volling P, Schroeder M: Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001, 50 (5): 1161-1171. 10.1016\/S0360-3016(01)01544-9.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"2450_CR5","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1093\/annonc\/mdj084","volume":"17","author":"G Folprecht","year":"2006","unstructured":"Folprecht G, Lutz MP, Schoffski P, Seufferlein T, Nolting A, Pollert P: Cetuximab and irinotecan\/5-fluorouracil\/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol. 2006, 17 (3): 450-456. 10.1093\/annonc\/mdj084.","journal-title":"Ann Oncol"},{"issue":"3","key":"2450_CR6","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/1040-8428(94)00144-I","volume":"19","author":"DS Salomon","year":"1995","unstructured":"Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995, 19 (3): 183-232. 10.1016\/1040-8428(94)00144-I.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"18S","key":"2450_CR7","doi-asserted-by":"crossref","first-page":"Abstract 3549","DOI":"10.1200\/jco.2006.24.18_suppl.3549","volume":"24","author":"H Wilke","year":"2006","unstructured":"Wilke H, Glynne-Jones R, Thaler J, : MABEL - A large multinational study of cetuximab plus irinotecan in irinotecan resistant metastatic colorectal cancer. J Clin Oncol. 2006, 24 (18S): Abstract 3549-","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"2450_CR8","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1016\/S0959-8049(01)00233-7","volume":"37","author":"J Baselga","year":"2001","unstructured":"Baselga J: The EGFR as a target for anticancer therapy--focus on cetuximab. Eur J Cancer. 2001, 37 (Suppl 4): S16-S22. 10.1016\/S0959-8049(01)00233-7.","journal-title":"Eur J Cancer"},{"issue":"19","key":"2450_CR9","first-page":"4637","volume":"53","author":"Z Fan","year":"1993","unstructured":"Fan Z, Baselga J, Masui H, Mendelsohn J: Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res. 1993, 53 (19): 4637-4642.","journal-title":"Cancer Res"},{"issue":"2","key":"2450_CR10","first-page":"701","volume":"6","author":"L Milas","year":"2000","unstructured":"Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K: In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res. 2000, 6 (2): 701-708.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2450_CR11","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMoa053422","volume":"354","author":"JA Bonner","year":"2006","unstructured":"Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006, 354 (6): 567-578. 10.1056\/NEJMoa053422.","journal-title":"N Engl J Med"},{"key":"2450_CR12","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1056\/NEJMc076359","volume":"357","author":"JA Bonner","year":"2007","unstructured":"Bonner JA, Ang K: More on severe cutaneous reaction with radiotherapy and cetuximab. N Engl J Med. 2007, 357: 1872-3. 10.1056\/NEJMc076359. author reply 1873","journal-title":"N Engl J Med"},{"key":"2450_CR13","unstructured":"Erbitux SmPC (Feb 2007). 2007, Ref Type: Report"},{"key":"2450_CR14","first-page":"Abstract 353","volume-title":"ASCO Gastrointestinal Cancer Symposium","author":"S Siena","year":"2007","unstructured":"Siena S, Glynne-Jones R, Thaler J: MABEL - A large mulitnational study of cetuximab plus irinotecan in irinotecan-resistant metastatic colorectal cancer: Update on infusion related reactions (IRR). ASCO Gastrointestinal Cancer Symposium. 2007, Abstract 353-"},{"key":"2450_CR15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000, 92: 205-216. 10.1093\/jnci\/92.3.205.","journal-title":"J Natl Cancer Inst"},{"key":"2450_CR16","unstructured":"Garcia-Huttenlocher HI, Timke C, Dinkel J, Huber PE, Debus J, Muenter MW: Acute Toxicity of Skin and Mucosa in Patients with Head and Neck Cancer Receiving Radiotherapy Alone or in Combination with Chemotherapy or Cetuximab. Proceedings of the 5th Annual ASTRO Meeting."},{"key":"2450_CR17","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMc071075","volume":"357","author":"W Budach","year":"2007","unstructured":"Budach W, B\u00f6lke E, Homey B: Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med. 2007, 357: 514-5. 10.1056\/NEJMc071075.","journal-title":"N Engl J Med"},{"key":"2450_CR18","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.radonc.2008.09.007","volume":"90","author":"C Giro","year":"2009","unstructured":"Giro C, Berger B, B\u00f6lke E, Ciernuk IF, Duprez F, Locati L, Maillard S, Ozsahin M, Pfeffer R, Robertson G, Langendijk JA, Budach W: High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: Results of a survey in EORTC institutes. Radiotherapy and Oncology. 2009, 90: 166-171. 10.1016\/j.radonc.2008.09.007.","journal-title":"Radiotherapy and Oncology"},{"key":"2450_CR19","unstructured":"RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clin Adv Hematol Oncol. 2007, 5 (2): 79-81."},{"issue":"7","key":"2450_CR20","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1200\/JCO.2004.00.1792","volume":"24","author":"DG Pfister","year":"2006","unstructured":"Pfister DG, Su YB, Kraus DH, Wolden SL, Lis E, Aliff TB: Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol. 2006, 24 (7): 1072-1078. 10.1200\/JCO.2004.00.1792.","journal-title":"J Clin Oncol"},{"key":"2450_CR21","first-page":"18s","volume":"27","author":"C Nutting","year":"2009","unstructured":"Nutting C, A'Hern R, Rogers MS, Sydenham MA, Adab F, Harrington K, Jefferies S, Scrase C, Yap BK, Hall E: First results of a phase III multicenter randomized controlled trial of intensity modulated (IMRT) versus conventional radiotherapy (RT) in head and neck cancer. 2009 ASCO Annual Meeting, Abstract No: LBA6006, Citation: J Clin Oncol. 2009, 27: 18s-(suppl; abstr LBA6006)","journal-title":"2009 ASCO Annual Meeting, Abstract No: LBA6006, Citation: J Clin Oncol"},{"key":"2450_CR22","first-page":"15s","volume":"27","author":"S Clavel","year":"2009","unstructured":"Clavel S, Nguyen D, Despr\u00e9s P, Fortin B, Coulombe G, Donath D, Souli\u00e8res D, Charpentier D, Guertin L, F P: Nguyen-Tan: Higher dose per fraction and shorter overall treatment time using intensity-modulated radiation therapy versus conventional radiation therapy with concurrent carboplatin and 5-fluorouracil for locally advanced oropharyngeal carcinoma: A comparison of toxicity and efficacy. 2009 ASCO Annual Meeting, Abstract No: 6038, Citation: J Clin Oncol. 2009, 27: 15s-(suppl; abstr 6038)","journal-title":"2009 ASCO Annual Meeting, Abstract No: 6038, Citation: J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-10-651.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-10-651\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-10-651","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-10-651.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T06:17:17Z","timestamp":1630477037000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-10-651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,26]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["2450"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-10-651","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,26]]},"assertion":[{"value":"22 May 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"651"}}